Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Puts Squeeze On SnugZ; Promo Product/OTC Drug Manufacturer Warned For CGMP Violations

Executive Summary

Known for its customizable lanyards and eyewear retainers, SnugZ USA, Inc. also manufactures sunscreens and other personal-care items for corporate branding purposes. The FDA inspected the firm’s West Jordan, Utah facility in late 2018, finding significant violations of current good manufacturing practices, according to a warning letter posted to the agency’s website 9 July.

You may also be interested in...



Sunscreens, Sanitizers In Tootsie Roll And Other Novelty Packaging Recalled

FDA also imposes import alert on lip balms, hand sanitizers and sunscreens made by Ningbo HuiZe Commodity in Zhejiang, China. Alert subjects products to detention without physical examination at US international ports of entry.

Skin Care Firms Get External Analgesic Treatment In FDA Warning Letters

Firms marketed products with label and other claims rendering them drugs but containing ingredients and label indications not part of OTC external analgesic TFM, recent warning letters say. Each firm also advised about GMP problems based on findings from Office of Regulatory Affairs' inspections and asked to hire regulatory consultants and provide detailed CAPAs.

Women’s Voices For The Earth Will Keep After CIR, Salon Worker Safety In 2024

Women’s Voices for the Earth continues to call attention to cosmetic ingredients’ potential health impacts on users including salon workers, while pushing the Cosmetic Ingredient Review to consider a wider variety of safety information in its assessment work.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148987

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel